Search
News Archive
Categories
algae
alternative energy
aquaculture
Aquapharm
Aquapreneur
astaxanthin
biofuel
biomaterials
bioprocessing
brown seaweed
chitin
chitosan
commercialize
cosmeceuticals
cosmetics
DHA
EPA
fish oil
fish protein
fucoidans
functional food
functional ingredients
glycomar
krill oil
marine biopolymer
marine bioprospecting
marine biotech cluster
marine biotechnology
marine drugs
marine enzymes
marine extract
marine ingredient
marine ingredients
marine microbe
marine natural product
marine organism
marine protein
microalgae
nutraceutical
omega 3
pharmaceutical
seafood byproducts
seaweed
sustainable
technology
New Aker JV to acquire EPAX in €70 million deal
Posted On: September 3, 2010Newly formed Trygg Pharma – a joint venture between krill player Aker BioMarine and New York-based private investment firm Lindsay Goldberg – has agreed to pay NOK 561 million (€71.2 million) for the Epax shares. Trygg will also assume the net interest bearing debt of Epax, which was NOK 314 million (€39.8 million) as of 31 December 2009.
The transaction – subject to the customary closing conditions – is expected to close in the final quarter of 2010, said the companies.
From Issue 11 • Categories: Tags: Aker Bio, Aker Biomarine, Epax, fish oil, krill oil, marine drugs, marine ingredient, marine ingredients, nutraceutical, omega 3, pharmaceutical • No Comments
Host
 |
Partners
  |
Sponsors
 |
 |
Share Aquapreneur
